IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stock Holdings Decreased by Quest Partners LLC

Quest Partners LLC reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 97.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 69 shares of the company’s stock after selling 2,415 shares during the period. Quest Partners LLC’s holdings in IDEXX Laboratories were worth $34,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Riverview Trust Co purchased a new position in shares of IDEXX Laboratories during the first quarter valued at $26,000. Crewe Advisors LLC purchased a new position in IDEXX Laboratories during the 1st quarter valued at about $26,000. Ridgewood Investments LLC purchased a new position in IDEXX Laboratories during the 2nd quarter valued at about $27,000. Institutional & Family Asset Management LLC acquired a new position in shares of IDEXX Laboratories in the 2nd quarter valued at about $28,000. Finally, DSM Capital Partners LLC acquired a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $33,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Up 1.1 %

IDEXX Laboratories stock opened at $517.06 on Friday. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The company’s fifty day moving average price is $483.57 and its two-hundred day moving average price is $500.01. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03. The company has a market capitalization of $42.70 billion, a price-to-earnings ratio of 50.05, a PEG ratio of 4.17 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a net margin of 22.34% and a return on equity of 57.03%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the company posted $2.67 EPS. The business’s revenue was up 6.4% on a year-over-year basis. On average, analysts forecast that IDEXX Laboratories, Inc. will post 10.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Stifel Nicolaus dropped their price objective on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research note on Monday, June 24th. BTIG Research initiated coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price target on the stock. Piper Sandler reduced their price objective on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a research report on Wednesday, August 14th. Finally, StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $582.25.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.